About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

The 5 Most Interesting Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call

By: StockStory

COLL Cover Image

Collegium Pharmaceutical’s second quarter results drew a positive market response, as management credited the performance to record revenues from its ADHD therapy Jornay and steady growth across its pain portfolio. CEO Vikram Karnani highlighted that Jornay prescriptions grew 23% year over year, fueled by expanded sales force efforts and targeted marketing initiatives. The company also noted that all three of its core pain medications delivered year-over-year revenue growth, underpinning the robust financial outcome. Management attributed the quarter’s success to continued execution on commercial expansion and the integration of new assets, as well as initial benefits from investments in awareness and prescriber outreach.

Is now the time to buy COLL? Find out in our full research report (it’s free).

Collegium Pharmaceutical (COLL) Q2 CY2025 Highlights:

  • Revenue: $188 million vs analyst estimates of $180.4 million (29.4% year-on-year growth, 4.2% beat)
  • Adjusted EPS: $1.68 vs analyst expectations of $1.85 (9.2% miss)
  • Adjusted EBITDA: $105.1 million vs analyst estimates of $103.7 million (55.9% margin, 1.4% beat)
  • The company lifted its revenue guidance for the full year to $752.5 million at the midpoint from $742.5 million, a 1.3% increase
  • EBITDA guidance for the full year is $447.5 million at the midpoint, above analyst estimates of $437.6 million
  • Operating Margin: 18.7%, down from 32.7% in the same quarter last year
  • Market Capitalization: $1.19 billion

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call

  • Leszek Sulewski (Truist Securities) asked about the targeted increase in prescribers for Jornay and the potential to revisit peak sales estimates. CEO Vikram Karnani said the company will reassess forecasts after evaluating the impact of sales force expansion and marketing investments, while Chief Commercial Officer Scott Dreyer emphasized ongoing growth in prescriber breadth and awareness.
  • Sulewski (Truist Securities) also questioned additional investments planned for the pain portfolio. Dreyer responded that investments remain steady and focused on maintaining current brand performance, with no significant shifts expected in sales or marketing spend.
  • John Todaro (Needham & Company) inquired about specific strategies to boost Jornay’s performance during the third quarter and competitive risks in the pain franchise. Dreyer highlighted the focus on awareness campaigns and leveraging the expanded sales team, while CFO Colleen Tupper detailed the regulatory and manufacturing hurdles that limit near-term generic competition.
  • David A. Amsellem (Piper Sandler) asked about the company’s approach to business development and whether it would consider non-pain or earlier-stage assets. Karnani stated the primary focus remains on commercial or commercial-ready assets that leverage existing infrastructure, with openness to other areas only under disciplined financial criteria.
  • Amsellem (Piper Sandler) also questioned the timing for pursuing pipeline or development-stage assets. Karnani indicated this could be considered after further portfolio expansion and scaling the business, but not in the immediate term.

Catalysts in Upcoming Quarters

In future quarters, our analysts will watch (1) the effectiveness of new sales and marketing initiatives in driving sustained prescription growth for Jornay, particularly as the back-to-school season unfolds, (2) how operating expense trends evolve as commercialization investments mature, and (3) any developments in potential generic entry timelines for the pain portfolio. Management’s execution on business development and capital deployment will also be key indicators of progress toward diversification goals.

Collegium Pharmaceutical currently trades at $38.35, up from $29.72 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

More News

View More
General Dynamics Hits New Highs: Why It Might Keep Climbing
Via MarketBeat
Tickers GD
Nike’s Turnaround: If the Shoe Fits, Buy It!
Via MarketBeat
Tickers NKE
NVIDIA Breaks Out to New Highs: What Comes Next?
Via MarketBeat
Topics Economy Stocks World Trade
Tickers CRWV META NVDA
Microsoft Stock Hits Stride in 2025—How Much More Can It Run?
Via MarketBeat
Topics Artificial Intelligence Retirement
Tickers MSFT
How Berkshire's OxyChem Buy Cements Its Long-Term Strength
Via MarketBeat
Tickers BRK BRK-A BRK-B OXY
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.